This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Toxic Stocks to Abandon or Sell Short for Solid Gains
by Zacks Equity Research
Overblown toxic stocks are usually vulnerable to external shocks and loaded with a huge amount of debt.
Covanta Holding (CVA) Q3 Earnings Miss, Revenues Top Mark
by Zacks Equity Research
Covanta Holding's (CVA) Q3 total revenues surpass expectations but the bottom line misses estimates.
Covanta (CVA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Covanta (CVA) delivered earnings and revenue surprises of -157.14% and 1.39%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Covanta (CVA) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Covanta (CVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alternative Energy Stock Outlook: Short-Term Prospects Bright
by Zacks Equity Research
Trump's hostile stance towards renewables failed to dent investors' confidence in the alternative energy industry. Impressively, the consensus estimate for the Zacks Alternative Energy-Other industry implies a decent year-over-year improvement
Ormat Technologies (ORA) Q2 Earnings Miss, Revenues Top
by Zacks Equity Research
Ormat Technologies' (ORA) total adjusted operating expenses surged 20.1% year over year to $20.8 million.
Covanta Holding (CVA) Q2 Loss Narrows, Revenues Beat Mark
by Zacks Equity Research
Covanta Holding's (CVA) Q2 loss gets narrower, mainly on account of year-over-year improvement at Fairfax plant coupled with improved waste pricing.
4 Toxic Stocks to Discard or Sell Short for Solid Gains
by Zacks Equity Research
Overblown toxic stocks are usually vulnerable to outside shocks and loaded with a high level of debt.
ORA vs. CVA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ORA vs. CVA: Which Stock Is the Better Value Option?
4 Toxic Stocks to Get Rid of or Sell Short for Solid Gains
by Zacks Equity Research
Overpriced toxic stocks are generally susceptible to outside shocks and burdened with a high level of debt.
4 Toxic Stocks to Discard or Sell Short for Solid Gains
by Zacks Equity Research
Pricey toxic stocks are usually susceptible to outside shocks and burdened with a high level of debt.
EQNR vs. CVA: Which Stock Is the Better Value Option?
by Zacks Equity Research
EQNR vs. CVA: Which Stock Is the Better Value Option?
FuelCell Energy (FCEL) Q2 Loss Wider Than Expected, Sales Top
by Zacks Equity Research
FuelCell Energy (FCEL) reports mixed results in second-quarter fiscal 2018 with revenue beat but wider-than-estimated loss per share.
EQNR or CVA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EQNR vs. CVA: Which Stock Is the Better Value Option?
Covanta Holding (CVA) Surges: Stock Moves 5.9% Higher
by Zacks Equity Research
Shares of Covanta Holding (CVA) appreciated nearly 6% yesterday
Zacks.com highlights: Covanta Holding, Altice USA, Incyte and Archrock
by Zacks Equity Research
Zacks.com highlights: Covanta Holding, Altice USA, Incyte and Archrock
Discard These 4 Toxic Stocks or Sell Short for Profit
by Zacks Equity Research
Overblown toxic stocks are usually susceptible to outside shocks and loaded with a huge amount of debt.
Covanta Holding (CVA) Jumps: Stock Rises 9.7%
by Zacks Equity Research
Covanta Holding Corporation (CVA) was a big mover last session, as the company saw its shares nearly 10% on the day amid huge volumes.
Why Covanta Holding (CVA) Could Be Positioned for a Slump
by Zacks Equity Research
Covanta Holding Corporation (CVA) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
Zacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation Entertainment
by Zacks Equity Research
Zacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation Entertainment
Zacks.com featured highlights: Covanta Holding, PTC, Etsy, KCG Holdings and Incyte
by Zacks Equity Research
Zacks.com featured highlights: Covanta Holding, PTC, Etsy, KCG Holdings and Incyte
Zacks.com featured highlights: PTC, Covanta Holding, Live Nation Entertainment, Incyte and Vertex Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights: PTC, Covanta Holding, Live Nation Entertainment, Incyte and Vertex Pharmaceuticals
Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals
Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals